SP1 and cancer: A modified hTERT promoter containing additional c-Myc- and Sp1-binding sites (mTERT) has been shown to induce stronger transcriptional activity than wild-type hTERT promoter can in tumour cells18, revealing that oncolytic adenoviruses replicating under the control of the mTERT promoter are good candidates for the treatment of cancers from various tissues of origin.